摘要:
New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
摘要:
New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
摘要:
New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
摘要:
New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
摘要:
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
摘要:
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
摘要:
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
摘要:
The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
摘要:
The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
摘要:
##STR1## Compounds of formula (I), and salts and prodrugs thereof, wherein X is O,S,NR 4 or CH 2 ; R 1 represents H, certain optionally substituted C 1-6 alkyl, or C 3-7 cycloalkyl; R 2 represents phenyl having certain optional substituents; R 3 represents C 1-6 alkyl, halo or NR 6 R 7 ; m is 2,3 or 4; n is 1,2,3,4,5,6 7 or 8 when X is CH 2 or 2,3,4,5,6,7 or 8 when X is O, S or NR 4 ; and x is 0,1,2, or 3; are CCK and/or gastrin antagonists. They and compositions thereof are therefore useful in therapy.
摘要翻译:式(I)化合物及其盐和前体药物,其中X为O,S,NR4或CH2; R1表示H,某些任选取代的C 1-6烷基或C 3-7环烷基; R2表示具有某些任选取代基的苯基; R 3表示C 1-6烷基,卤代或NR 6 R 7; m是2,3或4; 当X为CH 2时,n为1,2,3,4,5,6,7或8,X为O,S或NR4时为2,3,4,5,6,7或8; x为0,1,2或3; 是CCK和/或胃泌素拮抗剂。 因此,它们及其组合物可用于治疗。